Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

Anchored by TV spots and sports media placements, the Every Inch Matters campaign positions the projected number one overall ...

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

BridgeBio ( BBIO) rose 2.9% after a court filing appeared to indicate a settlement in a generic patent case over Pfizer's ( ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the ...

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

Pfizer’s GLP-1 weight management treatment Xianweiying is available for ‌pre-order in China, a Reuters check on ‌a local ...

April 24 (Reuters) - Bristol-Myers Squibb and Pfizer said on Friday they will start selling their jointly developed blood ...